Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Black Diamond Therapeutics, Inc. (BDTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1800+0.1600 (+7.92%)
At close: 01:00PM EST
2.3000 +0.12 (+5.50%)
After hours: 04:12PM EST
Advertisement

Black Diamond Therapeutics, Inc.

One Main Street
10th Floor
Cambridge, MA 02142
United States
617 252 0848
https://www.blackdiamondtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Dr. David M. Epstein Ph.D.Co-Founder, Pres, CEO & Director854.73kN/A1959
Dr. Fang Ni Pharm.D.CFO, Principal Financial Officer and Chief Bus. Officer639.23kN/A1987
Mr. Brent Hatzis-Schoch Esq., J.D.COO & Gen. Counsel610.48kN/A1965
Dr. Elizabeth Buck Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1975
Ms. Erika JonesVP of Fin., Corp. Controller & Principal Accounting OfficerN/AN/A1985
Ms. Elizabeth L. MontgomeryChief People OfficerN/AN/A1972
Dr. Christopher D. Roberts Ph.D.AdvisorN/AN/A1970
Mr. Tai-An Lin Ph.D.VP & Head of BiologyN/AN/AN/A
Dr. Sergey Yurasov M.D., Ph.D.Chief Medical OfficerN/AN/A1969
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Black Diamond Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement